Esperion, the Healthcare sector company, was revisited by a Wall Street analyst on September 19. Analyst Jason Zemansky from Bank of America Securities maintained a Sell rating on the stock and has a $1.60 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Jason Zemansky has given his Sell rating due to a combination of factors impacting Esperion’s stock. Although the company achieved a significant milestone with the approval of its lipid-lowering agent in Japan, which is expected to contribute positively to its global expansion, concerns remain about its performance in the US market. The approval in Japan, while beneficial, was largely anticipated and already factored into market expectations.
In contrast, the US market, which holds the largest potential for growth, is showing signs of stagnation. Despite the recognized value of the product, the uptake in the US is not meeting expectations, with recent script data indicating only modest growth. This slowdown in momentum, especially when compared to previous periods of double-digit growth, raises concerns about the product’s future trajectory in the US. Consequently, despite the promising international outlook, the underwhelming performance in the US market justifies the Sell rating, with a price objective set at $1.60.
According to TipRanks, Zemansky is a 4-star analyst with an average return of 12.8% and a 54.49% success rate. Zemansky covers the Healthcare sector, focusing on stocks such as Insmed, Madrigal Pharmaceuticals, and BridgeBio Pharma.